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(BBB) in the pathogenesis of Alzheimer's disease (AD). Although a relationship between apolipoprotein-,
cholesterol- and Aβ metabolism is evident, the interconnecting mechanisms operating in brain capillary
endothelial cells (BCEC) are poorly understood. ApoJ (clusterin) is present in HDL that regulates cholesterol
metabolism which is disturbed in AD. ApoJ levels are increased in AD brains and in plasma of cerebral
amyloid angiopathy (CAA) patients. ApoJ may bind, prevent fibrillization, and enhance clearance of Aβ. We
here define a connection of apoJ and cellular cholesterol homeostasis in amyloid precursor protein (APP)
processing/Aβ metabolism at the BBB. Silencing of apoJ in primary porcine (p)BCEC decreased intracellular
APP and Aβ oligomer levels while the addition of purified apoJ to pBCEC increased intracellular APP and
enhanced Aβ clearance across the pBCEC monolayer. Treatment of pBCEC with Aβ(1-40) increased
expression of apoJ and receptors involved in amyloid transport including lipoprotein receptor-related protein
1 [LRP1]. In accordance, cerebromicrovascular endothelial cells isolated from 3 x Tg AD mice showed
elevated expression levels of apoJ and LRP1 as compared to Non-Tg animals. Treatment of pBCEC with
HMGCoA-reductase inhibitor simvastatin markedly increased intracellular and secreted apoJ levels, in parallel
increased secreted Aβ oligomers and reduced Aβ uptake and cell-associated Aβ oligomers. Simvastatin effects
on apoJ, APP processing, and LRP1 expression in BCEC were confirmed in the mouse model. We suggest a
close and complex interaction of apoJ, cholesterol homeostasis, and APP/Aβ processing and clearance at the
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• Simvastatin shifts APP processing towards the non-amyloidogenic pathway in pBCEC 
• Inhibition of cholesterol synthesis by simvastatin up-regulates apoJ in pBCEC 
• Both, simvastatin and apoJ increase expression of APP and reduce Aβ uptake in 
pBCEC 
• Increased Aβ and simvastatin induce LRP1 and apoJ levels in vitro and in vivo  
• Thereby clearance of Aβ across the blood-brain barrier is facilitated 
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Amyloid-β peptides (Aβ) accumulate in cerebral capillaries indicating a central role of the 
blood-brain barrier (BBB) in the pathogenesis of Alzheimer’s disease (AD). Although a 
relationship between apolipoprotein-, cholesterol- and Aβ metabolism is evident, the 
interconnecting mechanisms operating in brain capillary endothelial cells (BCEC) are poorly 
understood. ApoJ (clusterin) is present in HDL that regulates cholesterol metabolism which is 
disturbed in AD. ApoJ levels are increased in AD brains and in plasma of cerebral amyloid 
angiopathy (CAA) patients. ApoJ may bind, prevent fibrillization, and enhance clearance of 
Aβ. We here define a connection of apoJ and cellular cholesterol homeostasis in amyloid 
precursor protein (APP) processing/Aβ metabolism at the BBB. Silencing of apoJ in primary 
porcine (p)BCEC decreased intracellular APP and Aβ oligomer levels while the addition of 
purified apoJ to pBCEC increased intracellular APP and enhanced Aβ clearance across the 
pBCEC monolayer. Treatment of pBCEC with Aβ(1-40) increased expression of apoJ and 
receptors involved in amyloid transport including lipoprotein receptor-related protein 1 
(LRP1). In accordance, cerebromicrovascular endothelial cells isolated from 3xTg AD mice 
showed elevated expression levels of apoJ and LRP1 as compared to Non-Tg animals. 
Treatment of pBCEC with HMGCoA-reductase inhibitor simvastatin markedly increased 
intracellular and secreted apoJ levels, in parallel increased secreted Aβ oligomers and 
reduced Aβ uptake and cell-associated Aβ oligomers. Simvastatin effects on apoJ, APP 
processing, and LRP1 expression in BCEC were confirmed in the mouse model. We suggest 
a close and complex interaction of apoJ, cholesterol homeostasis, and APP/Aβ processing 




Over the past 20 years extensive research and effort has been put into understanding the 
mechanisms and biochemical pathways underlying Alzheimer’s Disease (AD). To date there 
are two known main pathological hallmarks in the development of the disease (1): (i) 
abnormally phosphorylated tau proteins forming intracellular neurofibrillary tangles and (ii) 
deposits of differently sized amyloid beta peptides (Aβ) which oligomerize and form 
extracellular amyloid plaques surrounded by dystrophic neurites and microglia (2,3). In the 
last decade it became increasingly evident that AD patients display biochemical, 
morphological and functional changes in the cerebrovasculature caused by Aβ deposition in 
arteries and arterioles, but also in capillaries (4–6). This accumulation of Aβ within the walls 
of cerebral capillaries may trigger capillary cerebral amyloid angiopathy (CAA) (7), which 
may cause brain hypoperfusion that further stimulates Aβ production (8), altogether implying 
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a thus far underestimated role of the blood-brain barrier (BBB) in the (early) pathogenesis of 
AD.  
 
Among various hypotheses of AD development, the amyloid cascade hypothesis, 
suggesting the formation of amyloid plaques from Aβ peptides, receives the most attention 
(9,10). The amyloid precursor protein (APP) is processed by two competing pathways, the 
non-amyloidogenic and the Aβ generating pathway. Sequential cleavage of the 
transmembrane protein APP by caspase-like enzymes β-secretase (BACE-1) and γ-
secretase leads to formation of C-terminal fragment β (CTFβ) and neurotoxic Aβ peptides. 
Alternatively and prevailing under normal physiological conditions, APP is processed by α-
secretase (ADAM10) followed by γ-secretase to form CTFα and cellular secretion of the non-
amyloidogenic and neuroprotective sAPPα fragment. 
 
Martins et al. reported that AD and atherosclerosis patients reveal similar lipoprotein and 
cholesterol profiles (11). It appears strikingly that high levels of plasma cholesterol and LDL 
in mid life (12) and particularly low levels of high-density lipoproteins (HDL) and 
apolipoprotein (apo)A-I significantly correlate with the development and progression of AD 
(13). Bates et al. described that high HDL serum levels correlate with improved verbal 
learning and memory performance (14). Cholesterol metabolism in the brain, however, is 
separated from that in other parts of the body (15). HMGCo-A reductase is the rate-limiting 
enzyme in cholesterol synthesis, which can be pharmacologically inhibited by statins (16). 
Unlike most other statins, part of simvastatin in the circulation is able to cross the BBB (17). 
Although the use of statins in AD remains controversial, beneficial effects of simvastatin 
treatment on amyloidosis and Aβ plaque load have been observed in several in vivo studies 
(18–21). In addition, recent studies reported beneficial effects of statin treatment explicitly at 
the BBB, where simvastatin was shown to ameliorate cerebrovascular integrity (22).  
 
Continuous removal of Aβ from the brain is crucial to prevent the development of amyloid 
plaques and the progression of AD. Aβ peptides can be removed from the brain through 
various clearing mechanisms (23). Soluble Aβ can be either taken up by microglia and 
astrocyte phagocytosis. Another way is through brain interstitial fluid (ISF) bulk flow 
clearance, which involves CSF sink and perivascular clearance mechanisms. However, the 
majority of Aβ peptides appear to be removed through active transport across the BBB, thus 
representing the most important clearance pathway (24). A range of receptors have been 
identified to be involved in uptake and transport of Aβ fragments across the BBB. Among 
others, receptor for advanced glycation end products (RAGE) and low-density lipoprotein 
receptor-related protein 1 (LRP1) are proposed to be the major receptors responsible for the 
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transport of Aβ from the plasma and the brain parenchymal side across the BBB, 
respectively (25). The outcome of recent studies suggests a link between LRP1 expression 
and CAA (26). The 600 kDa LRP1 precursor protein is synthesized and subsequently 
cleaved in the endoplasmic reticulum and golgi-apparatus (27). LRP1 consists of an α- (515 
kDa) and a transmembrane β- (85 kDa) chain, which can be further cleaved by 
metalloproteinases, like ADAM10, and secretases, like BACE1, to generate soluble LRP1 
(sLRP1) (28,29). Since sLRP1 is mainly present in the circulation it has been suggested to 
be the main carrier of Aβ in plasma (25). sLRP1 has been also linked to lipid metabolism and 
the formation and release of sLRP1 in vascular cells is hypothesized to be stimulated by 
hypercholesterolemia (30).  
 
Lipoproteins detected in the central nervous system (CNS) reveal a density similar to HDL 
(31,32). Besides its major task to eliminate excess tissue cholesterol through reverse 
cholesterol transport mediated by specific ATP binding cassette (ABC) transporters, HDL is 
also able to bind Aβ and clear the peptides across the BBB. The most abundant 
apolipoprotein - and most well-known genetic risk factor for AD - is apolipoprotein E (apoE) 
that also associates with HDL-like particles in the brain (33). ApoE functions as the major 
cholesterol carrier (followed by apoA-I) regulating lipid homeostasis and thereby mediating 
lipid transport from one tissue or cell type to another (34). Brain apoE is mainly produced by 
astrocytes and supports cholesterol transport to neurons via binding to a number of receptors 
of the LDL receptor family (34). Genome-wide association studies have identified 3 alleles of 
apoE (ε2, ε3, ε4) with the ε4 allele of APOE as the strongest genetic risk factor for AD 
affecting Aβ aggregation and clearance (34). Next to apoE and apoA-I, apoJ, also known as 
clusterin, is among the major apolipoproteins associated with brain HDL-like particles 
(35,36). ApoJ is an ubiquitously expressed protein firstly described in 1983 in ram rete testis 
fluid (37). Although highest expression levels of apoJ were detected in brain, only a few 
studies have investigated its physiological behaviour in the brain. Next to its role in  
lipid/cholesterol transport and trafficking in the brain (38), apoJ reveals a chaperone function 
(39). Two independent genome-wide association studies identified gene encoding apoJ in 
addition to the well-established apoE4 gene, as a novel susceptibility locus for late-onset AD 
(40,41). ApoJ expression was reported to be increased in AD, especially in neuritic plaques 
and cerebrovascular deposits (36). A recent study reported increased plasma apoJ levels in 
CAA patients as compared to AD patients or controls (42). ApoJ is able to avidly bind Aβ, 
prevent their fibrillization, and enhances Aβ endocytosis by glial cells (36). Importantly, 
Zlokovic et al. revealed that upon binding to apoJ, Aβ peptides can be cleared across the 




We earlier reported that primary porcine brain capillary endothelial cells (pBCEC) express 
all key enzymes involved in APP processing, i.e. α-, β-, and γ-secretases, that pBCEC 
synthesize APP, sAPPα, and Aβ (oligomers), and that modulation of cellular cholesterol 
metabolism by liver-X receptor (LXR) ligands or cholesterol modulates APP processing in 
BCEC (44). The goal of the present study was to establish the role of apoJ in cholesterol and 
Aβ metabolism in cerebromicrovascular endothelial cells by using both a well-established in 
vitro model consisting of primary, porcine BCEC, as well as murine BCEC isolated from 3xTg 
AD model mice or Non-Tg controls after simvastatin treatment. We here demonstrate that 
cholesterol homeostasis in BCEC, APP processing, Aß clearance, and expression and 
secretion of apoJ are complexly linked and influence each other at the level of the BBB. 
 
2. MATERIALS AND METHODS 
 
2.1. Materials 
Cell culture flasks, plates, and other plasticware were purchased from Greiner Bio-One 
(Kremsmünster, Austria). Cell culture medium M199 and MCDB131, minimal essential 
medium, DMEM/F-12 (Ham’s), porcine serum, and dispase were purchased from Life 
technologies; collagen G from bovine calf skin was obtained from Biochrom (Berlin, 
Germany), and cell culture additives were from PAA laboratories (Pasching, Austria). 
Collagenase/dispase was from Roche Applied Science. Transwell multiwell plates (polyester 
membrane inserts, 0.4 µm pore size) as well as simvastatin, cholesterol, hydrocortisone, 
Percoll (pH 8.5- 9.5) and Aβ(1-40) (D-A-E-F-R-H-D-S-G-Y-E-V-H-H-Q-K-L-V-F-F-A-E-D-V-G-S-
N-K-G-A-I-I-G-L-M-V-G-G-V-V; ≥90% (HPLC)) were purchased from Sigma-Aldrich. 24(S)-
hydroxycholesterol was purchased from Medical Isotopes (Pelham, Canada), 27-
hydroxycholesterol from Avanti Polar Lipids, Inc., and TO901317 from Cayman Chemicals. 
Dextran was purchased from VWR. [14C]-sucrose, Ultima Gold scintillation cocktail, and 
scintillation vials were purchased from Perkin Elmer. [125I]-amyloid β peptide (1-40) was 
obtained from Phoenix Pharmaceuticals. Small interfering RNAs (siRNA) targeting for apoJ 
were from Microsynth (Switzerland). siRNA transfection reagents were obtained from Lonza, 
and negative siRNA control from Dharmacon. Polyvinylidene fluoride (PVDF; 0.45 µm) 
transfer membranes were purchased from GE healthcare. Antibodies used for in vitro studies 
were obtained from Sigma-Aldrich (β-actin Cat#A2066, goat anti-mouse-HRP Cat#A0168), 
Invitrogen (Rabbit anti-β-Amyloid Precursor Protein Cat#51-2700), Millipore (A11 rabbit anti- 
Amyloid Oligomer, aβ, oligomeric, Cat# AB9234), Biolegend (Purified anti-β-Amyloid, 1-16 
Antibody, Clone:6E10, Cat# 803002)  Cloud-Clone Corp. (Polyclonal Antibody to Clusterin 
(CLU), PAB180Po01) and Santa Cruz Biotechnology (goat anti-rabbit IgG-HRP, Cat# sc-
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2030). Antibodies raised against various LRP1 fragments were obtained from AG Pietrzik, 
Johannes-Gutenberg-University Mainz, Germany. For immunoblot analysis of mBCEC, 
primary antibodies were purchased from Sigma-Aldrich (Anti- Amyloid Precursor Protein, C-
Terminal, Cat#A8717) and from Santa Cruz Biotechnology (clusterin/apoJ (H-330), Cat# sc-
8354). Simvastatin used for animal studies was purchased from MSD Austria. PCR reagents 
were from Bio-Rad and primers were purchased from Invitrogen. Pre-validated primers were 
purchased from Qiagen (QuantiTect Primer Assay). All other reagents and chemicals were 
purchased either from Sigma-Aldrich or Merck. 
 
2.2. Isolation and culture of porcine brain capillary endothelial cells (pBCEC) 
pBCEC were isolated from 3 hemispheres of freshly slaughtered pigs from the local abattoir 
(45). Forceps were used to remove meninges and capillaries. A scalpel and a cutter with 
rolling plates were used to mince the grey and white matter of the brain cortex. To isolate the 
capillaries, dispase (70 mg/brain) was mixed with 40 ml M199 medium (containing 1% 
penicillin/streptomycin, 1% gentamycin, 1 mM L-glutamine) and incubated at 37°C in the 
water bath for 1 h with gentle stirring. 150 ml dextran solution was added and the suspension 
was centrifuged (6,800xg, 10 min, 4°C). The pellet was resuspended in M199 medium 
(containing 1% penicillin/streptomycin, 1% gentamycin, 1 mM L-glutamine and 10% porcine 
serum) and the capillaries were disrupted mechanically by filtering the suspension through a 
nylon mesh and enzymatically by adding 350 µl collagenase/dispase. The suspension was 
carefully pipetted onto a Percoll bi-phase gradient (15 ml of 1.07 g/ml Percoll solution on 
bottom, 20 ml of 1.03 g/ml Percoll solution on top) and centrifuged (1300xg, 10 min) in a 
swinging bucket rotor. Endothelial cells were isolated from the interphase by aspiration and 
cells were plated on to collagen coated 75 cm² cell culture flasks in M199 medium 
(containing 1% penicillin/streptomycin, 1% gentamycin, 1 mM L-glutamine, and 10% porcine 
serum). After 26 h of incubation, endothelial cells were washed twice with PBS and cultured 
in M199 (containing 1% penicillin/streptomycin, 1 mM L-glutamine and 10% porcine serum) 
until confluent. Confluent cells were trypsinized and split onto collagen-coated multiwell 
plates (60 µg/ml collagen) or transwells (120 µg/ml collagen) for further experiments. All cell 
culture incubations were performed at 37°C in humidified air containing 5% CO2. 
 
2.3. Activation of simvastatin 
Before simvastatin was used in in vitro cell culture experiments, it was activated by opening 
the lactone ring. Activation was performed according to the protocol provided by Merck 
(46,47). In brief, 1 mg of simvastatin was dissolved in 0.1 ml of absolute ethanol and 
subsequent addition of 150 µl 0.1 N NaOH. The solution was heated at 50 °C for 2 h and 
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neutralized to pH 7.2 with 1 N HCl. The solution was brought to a final volume of 4 mg/ml 
with distilled water and stored at −20 °C until use. 
 
2.4. Transwell experiments 
To establish polarized pBCEC cultures, cells were plated onto collagen-coated (120 µg/ml) 
transwell (6- or 12-well) culture dishes at a density of 40,000 cells/cm2. Cells were grown for 
2–3 days depending on the transendothelial electrical resistance (TEER; 50 ohms/cm2). The 
tightness of the transwell culture was assessed by measuring TEERs using an EndOhm 
tissue resistance measurement chamber and EndOhm ohmmeter (World Precision 
Instruments, Florida). TEERs of collagen-coated, cell-free filters were used as blanks. Tight 
junction formation was induced (overnight) by adding DMEM/Ham’s F-12 medium containing 
550 nM hydrocortisone, 1% penicillin/streptomycin, and 0.7 mM L-glutamine along with 
cholesterol [100 µM], simvastatin [5 µM], or vehicle only (EtOH, 0.5 %). Establishment of 
intact tight junctions was indicated by TEERs rising between 300 and 1000 ohms/cm2 in the 
in vitro BBB model system.  
 
2.5. Animal studies 
Animal studies were performed with ethical approval of the Austrian Department of Science, 
Research and Economy (approval number 66010/0052-WF/V/3b/2015). Female 3xTg AD 
mice and non-transgenic (Non-Tg) C57/Bl6 Mice were maintained in a 12-h light/ 12-h dark 
cycle in a temperature-controlled environment with free access to chow diet (Ssniff, 
Germany). Aged mice (Non-Tg: 58 ± 11 weeks, 3xTg AD: 64 ± 4 weeks) were gavaged for 
21 days with vehicle only or 40 mg/kg simvastatin in 0.2% agarose in PBS. Blood samples 
were taken prior to treatments and upon sacrification. Plasma lipids were measured 
enzymatically using colorimetric assay kits (DiaSys Diagnostic Systems; Supplemental Fig.I).  
 
2.6. Isolation of mBCEC 
Mice were sacrificed and murine brain capillary endothelial cells (mBCEC) were isolated 
from a pool of 2 hemispheres (Non-Tg +/-sim: n=4; 3xTg +/-sim: n=8). In brief, hemispheres 
were washed in PBS (containing 2% penicillin/streptomycin) and the olfactory bulb was 
removed. Scalpel and douncer were used to mince the grey and the white matter of the 
cortex. To isolate the capillaries, the homogenate was mixed with dispase (0.01 g /2 
hemispheres) in 5 ml MCDB131 medium (containing 2% FBS, 1% L-glutamine and 10% 
penicillin/streptomycin) and incubated at 37°C in the water bath for 1 h. Disruption of the 
capillaries followed by endothelial cell isolation using Percoll bi-phase gradient was 





2.7. Isolation of plasma-derived apoJ 
 ApoJ was isolated from human plasma as described by Dabbs and Wilson (49). In brief, 
plasma was prepared by centrifuging human blood containing 10 mM sodium citrate. After 
addition of Complete® protease inhibitor, debris was removed with a GFC glass fibre filter 
(MicroAnalytic Products Inc., Mountain Lakes, NJ, USA) and a 0.45 µm cellulose nitrate filter. 
ApoJ was isolated from the plasma using a G7 anti-CLU monoclonal antibody column (50) 
connected to an Econo pump system (Biorad). ApoJ bound to the column was eluted using 2 
M GdHCl in PBS and dialysed against 20 mM MES, pH 6.0. A 1 ml HiTrap™ SP XL cation 
exchange column (GE healtchcare) was used to collect apoJ from the dialysed fraction. 
 
2.8. Lipid extraction and GC-MS analysis 
For measuring brain cholesterol and precursors (Supplemental Fig.II), hemispheres of 
murine brains were subjected to lipid extraction according to the Folch method. Folch 
solution (chloroform/methanol, 2:1 (v/v)) was added and tissues homogenized using an Ultra-
turrax T25 basic (IKA). After 2 h at room temperature, vials were centrifuged (840 g, 10 min), 
and extracts transferred to new vials, solvents evaporated under argon, and redissolved in 
appropriate volumes of Folch and stored at −20 °C until measurements.  
For measuring cellular cholesterol precursors, pBCEC were cultured in 75 cm² flasks until 
confluent and incubated for 24 h in the absence or presence of 5 µM simvastatin in serum-
free medium. For measuring cholesterol synthesis, pBCEC were incubated for 24h with 
simvastatin [5 µM] and vehicle control (0.5% ethanol) in the presence of 10% deuterium 
water (D2O) in serum-free medium. Cellular lipids were extracted with Folch’s solution 
(chloroform:methanol= 2:1 (v/v)) for 30 min at room temperature.  
Cholesterol precursors and deuterium enrichment in newly synthesized cholesterol was 
determined using combined gas chromatography-mass spectrometry (GC-MS) analysis as 
described previously (51). In brief, after lipid extraction certain amounts of the extract were 
hydrolyzed in 1 M NaOH in ethanol and incubated in a water bath for 1 h at 65°C. 
Cyclohexane was used to extract the organic phase which then was evaporated and silylated 
by treating with pyridine/ hexamethyldisilazane/ chlorotrimethylesilane (3:2:1, v/v/v) at 60°C 
for 30 min. After evaporation of the solvent, hexane was added and then transferred into 
special glass vials. Cholesterol precursors were determined using deuterium-labeled internal 
standards (d6-cholesterol, d4-lathosterol and d6-sitosterol). GC-MS analysis was performed 
as described previously on a Hewlett Packard 6890 Series Plus gas chromatograph using a 
gas chromatograph column (52). Enrichment of deuterium in cellular cholesterol was 




2.9. BACE Activity Assay 
The activity of β-secretase BACE1 was examined using the Beta Secretase Activity Assay 
Kit from Abcam. In brief, pBCEC were treated with vehicle control (ethanol) or simvastatin 
[5µM] for 24 h followed by treatment with lysis buffer and subsequent determination of BACE 
activity using 100 µg of cellular protein. Activity was measured fluorescently using a 
fluorimeter (FlexStation II, Molecular Devices; Ex= 345 nm/Em: 500 nm). 
 
2.10. Isolation of RNA and quantitative real-time PCR 
pBCEC were grown in 12-well plates and incubated in serum-free M199 medium with 
vehicle control (0.5% ethanol), 24(S)-hydroxycholesterol [10 µM], 27-hydroxycholesterol 
[10µM], TO901317 [2µM], cholesterol [100 µM], simvastatin [5 µM], purified apoJ [2 µg/ml or 
20 µg/ml], or increasing concentrations of soluble Aβ(1-40) [25 ng/ml, 50 ng/ml or 200 ng/ml]. 
In addition, pBCEC were incubated with a combination of plasma-derived apoJ [2µg/ml] and 
Aβ(1-40) [50 ng/ml] after a 30 min preincubation in serum-free M199 medium at 37°C. For cell 
culture experiments, simvastatin was activated prior to use according manufacturer’s 
protocol (54). Cells from 3 wells were pooled and resuspended in 1 mL TriReagent RT 
(MRC, USA). For animal studies, RNA was isolated from cell lysates of mBCEC using 1ml 
TriReagent RT. Whole brain mouse tissue (~50 mg) was minced by adding 1 ml TriReagent 
RT and by using a tissue homogenizer (Ultra Turrax) for 3x10 seconds. To reach a phase 
separation, 50 µl 4-bromoanisole (BAN) was added, the suspension was incubated for 5 min 
at room temperature and centrifuged (12 000xg, 15 min, 4°C). The aqueous phase of the 
suspension was isolated and mixed with isopropanol 1:1 (v/v). After 10 min of incubation at 
room temperature and a centrifugation step (12 000xg, 8 min, 4°C), the pellet was washed 
once with 75% ethanol. The RNA pellet was air dried and resuspended in 40 µl RNase free 
water. To dissolve the RNA, the samples were incubated for 10 min in the thermocycler 
(55°C, 300 rpm) and the concentration and purity was determined using a Nanodrop. 
Relative gene expression levels were determined by reverse transcriptase (RT)-quantitative 
real-time PCR (qPCR) based on SYBR Green detection chemistry. For cDNA synthesis the 
“High Capacity Reverse Transcriptase Kit” by Life Technologies was used according to 
manufacturer’s instructions. On average, 500 ng of RNA was reversed to receive a final 
concentration of 5 ng/µl of cDNA. Control reactions lacking reverse transcriptase were 
prepared in order to check for genomic DNA contamination. qPCR were prepared by using 
SYBR Green Master Mix (Biorad) according to the manufacturer’s recommendations. In 
general, each reaction (10 µl) contained 1×iQ SYBR Green Supermix (Bio-Rad), 300 nmoles 
of each primer (Table 1), and 10 ng of cDNA template; PCR cycling conditions consisted of 
40 cycles at 95 °C for 20 s, 60 °C for 40 s, and 72 °C for 40 s. All reactions were run in 
triplicates, and melting curve analyses were routinely performed to monitor the specificity of 
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the PCR product. Relative gene expression was quantified by using the ∆∆Ct method 
described by Livak and Schmittgen (55). 
 
2.11. RNA interference mediated apoJ silencing in pBCEC 
A pool of 3 small interfering (si)RNA targeting apoJ mRNAs was purchased from 
Microsynth. At 50-60% confluency, pBCEC were transfected with 25 nM and 50 nM of the 
prepared mix of the 3 apoJ siRNAs (Table 2) using PrimeFect Diluent and PrimeFect 
Reagent as described by Stefulj et al. (56). Transfected cells were incubated for 28-30 h at 
37°C. In parallel, silenced pBCEC were incubated with 5 µM simvastatin for 24 h, and/or 50 
ng/µl Aβ(1-40) for additional 1 h in serum-free conditions. Scrambled siRNA was used as non-
coding siRNA with minimal unintended off-target effects.  
 
2.12. SDS-PAGE and immunoblotting 
pBCEC were grown in 6-well plates and incubated with serum-free medium containing 
vehicle control (0.5 % ethanol), 24(S)-hydroxycholesterol [10 µM], 27-hydroxycholesterol 
[10µM], TO901317 [2µM], cholesterol [100 µM], simvastatin [5 µM], purified apoJ [2 µg/ml or 
20 µg/ml], and/or increasing concentrations of soluble Aβ(1-40) [25 ng/ml, 50 ng/ml or 200 
ng/ml]. Additionally, pBCEC were treated with a combination of plasma-derived apoJ [2µg/ml] 
and Aβ(1-40) [50 ng/ml] after 30min preincubation at 37°C. For cell culture experiments, 
simvastatin was activated prior to use according manufacturer’s protocol (54).  Intracellular 
and secreted proteins were isolated after an incubation period of 1 h and 24 h. To isolate 
secreted proteins, the medium was collected and centrifuged at 10 000xg for 10 min at 4°C. 
Proteins were precipitated by adding 3% (v/v) trichloroacetic acid (TCA), and incubation for 1 
h on ice. The suspension was centrifuged (10 000xg, 10 min, 4°C), the pellet was washed 
twice with ice cold acetone, and dissolved in 1x sample buffer (Biorad) and 1x Reducing 
Agent (Biorad). After removing the medium from the 6-well plates, cells were washed twice 
with cold 1x PBS and lysed in protein lysis buffer (50 mm Tris, 10 mm EDTA, 1% Triton X-
100, 0.5% v/v protease inhibitor mixture, pH 7.4). Cell lysates were vortexed, sonicated in a 
water bath sonicator for 2x3 min, and centrifuged (10 000xg, 10 min, 4°C) to remove residual 
DNA. Protein concentrations were measured by the BCA assay (Thermo Scientific) and 15 
µg of the proteins (mixed with 1x loading buffer, 1x reducing agent) were loaded onto 
NuPage® Novex 4-12% Bis- Tris Midi Gels (Thermo Scientific) after proteins were denatured 
at 95°C for 5 min in a thermocyler. Proteins were separated by SDS-PAGE using the method 
described by Laemmli (57). Western blotting was performed according to Haid and Suissa 
(58) using 0.45 µm PVDF membranes (GE healthcare). After blocking with 5% non-fat dry 
milk (Biorad) in TBS-TT for 1 h the membrane was probed with rabbit polyclonal anti-APP 
antibody (Invitrogen; 1:1000), rabbit polyclonal A11 anti-amyloid oligomers antibody 
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(Millipore; 1:10 000), rabbit polyclonal anti-APP/CTF (Sigma, 1:4000), rabbit polyclonal anti-
apoJ (Cloud-Clone Corp, 1:500; Santa Cruz Biotechnology, 1:500), goat anti- LRP1 1704 
(1:10 000), mouse anti- LRP1 B411E2 (1:1000), or rabbit polyclonal anti-β-actin (Sigma; 
1:5000) overnight at 4°C. After incubation of the blot with the adequate HRP-conjugated 
secondary antibody, signals were detected using Clarity Western ECL Substrate (Biorad) 
and exposure to x-ray films (Thermo Scientific). Films were scanned and bands 
densitometrically analyzed using Image J software (version 1.47v). Immunoblot analysis of 
mBCEC was performed using cell lysates of freshly isolated mBCEC without cultivation.  
  
2.13. Aβ uptake studies 
pBCEC were grown in collagen-coated 24-well plates until confluent and incubated with 
vehicle control (ethanol) or simvastatin [5 µM] for 24 h. Aβ uptake assay was performed by 
adding 0.3 nM of [125I]-Aβ(1-40) and incubating at 37°C for 22 h. Alternatively, for examining 
uptake of Aβ(1-40) in combination to treatment with purified apoJ [2 µg/ml or 20 µg/ml], Alexa 
Fluor 488 (AF488) labelled Aβ(1-40) was used and pBCEC were incubated at 37°C for 3 h and 
24 h. To allow complex formation apoJ was incubated with AF488-Aβ(1-40) at 37°C for 30 min 
prior to cell treatment. Cells were washed twice with ice-cold PBS and medium and PBS 
were collected and subjected to TCA precipitation (30%TCA). Cells were lysed by adding 0.3 
N NaOH and subsequently subjected to protein precipitation with 100% TCA. Total cellular 
protein concentration was quantified using the Qubit fluorometer (Quant-IT protein assay kit, 
Invitrogen). Uptake of 125I-Aβ(1-40) was calculated as the percentage of cpm/mg cell protein in 
the pellet of cell lysates relative to the pellet of supernatants. Uptake of AF488-Aβ(1-40) was 
determined using a fluorescent plate reader. 
 
2.14. Aβ transport studies 
pBCEC were grown on collagen coated [120 µg/ml] 12-well transwell filters, incubated in 
DMEM/Ham’s F12 medium containing 1% P/S, 0.25% glutamine (Sigma Aldrich). Cells were 
grown for 2-3 days depending on the transendothelial electrical resistance (TEER). TEER 
was measured by using an EndOhm tissue resistance chamber and the Evohm ohmmeter 
(World Precision Instruments). Tight junction formation was induced (overnight) by adding 
550 nM hydrocortisone to DMEM/Ham’s F-12 medium containing 1% penicillin/streptomycin, 
and 0.7 mM L-glutamine. To test effects on Aβ(1-40) transport, pBCEC were incubated with 5 
µM simvastatin prior to transcytosis experiment. In additional experiments, 2 µg/ml of apoJ 
was added to the basolateral compartment. Aβ transport assay was performed by adding 0.3 
nM [125I]-Aβ(1-40) and 100 nM [
14C]-sucrose as non-diffusion control to the basolateral 
compartment of transwell chambers. Transport of [125I]-Aβ(140) from the basolateral/input 
(‘brain parenchymal’) to the apical/acceptor (‘blood’) compartment was studied during 2 h. 
12 
 
From each input and apical (acceptor) compartment, respectively, 400 µl and 50 µl were 
taken to examine transport of [125I]-Aβ(1-40) and  [
14C]-sucrose. [14C]-sucrose was used as 
paracellular transport control which is not taken up by cells (59). To detect transport of intact 
[125I]-Aβ(1-40), 400 µl aliquots of media  were subjected to TCA precipitation and pellets were 
counted on a γ-counter. 50 µl of input and acceptor were counted on a β-counter with 5 ml 
Ultima Gold scintillation cocktail to examine passive diffusion of [14C]-sucrose across the 








2.15. Cytotoxicity assay 
Cytotoxicity assay was performed using cell proliferation Reagent WST1 by Roche. In brief, 
pBCEC were plated onto collagen coated [60 µg/ml] 96 well plates. Upon reaching 
confluency, cells were treated for 24 h with increasing concentrations of Aβ(1-40) [25 ng/ml, 50 
ng/ml, or 200 ng/ml]. Absorbance of the formazan product was measured using fluorimeter 
FlexStation II (Molecular Devices) at 450 nm when 650 nm was used as reference 
wavelength. 
 
2.16. Single/double labeled immunofluorescence staining of pBCEC  
Cerebrovascular endothelial cells were cultured on Lab-Tek chamber slides (Thermo Fisher 
Scientific, NY, USA) and were fixed with 4% paraformaldehyde (PFA) for 10 min. After 
fixation, cells were washed in TBST and blocked with donkey serum for 30 min before 
primary antibodies incubation for 1 h (rabbit anti-human Zo-1/ TJP1 1.0µg/ml (Thermo Fisher 
Scientific, IL, USA), mouse anti-human VE-cadherin (F-8) 0.4µg/ml) (Santa Cruz 
Biotechnology, Inc., TX, USA) and anti-rabbit Lrp1 (1704)- obtained from Prof. Claus Pietrzik. 
All incubation steps were performed in a dark moist chamber at room temperature. After 5 
min of TBST wash, secondary antibodies were applied: donkey anti-rabbit Cy-3 (red) 
2.0µg/ml (Jackson Immuno Lab, Inc., West Grove, PA, USA) and donkey anti-mouse Dylight 
488 (green) 1.67µg/ml (Jackson Immuno Lab, Inc., West Grove, PA, USA) for 30 min. After 
rinsing in TBST, DAPI was added to the slides for 20 min as a nuclei counter stain. Sections 
were rinsed again with TBST before mounting with Vectashield mounting medium (Vector 
Lab, Inc., Burlingame, CA, USA). Normal rabbit immunoglobulin fraction (Millipore Corp., 
Temecular, Ca, USA) and mouse immunoglobulin fraction (CedarlaneLab, Burlington, NC, 
USA) were used as negative controls. To acquire and analyze computerized images of 
sections and cells, a Leica DM4000 B microscope (Leica Cambridge Ltd) equipped with 





Results are reported as mean±SD unless stated otherwise. All experiments were performed 
at least three or more times in triplicates. Statistical significances (*p<0.05: **p<0.01; ***p< 
0.001) were determined by analysis of variance (ANOVA) or two-tailed Student’s t-test 




3.1. Simvastatin stimulates expression and secretion of apoJ in cerebrovascular 
endothelial cells 
To investigate regulatory effects of modulators of cholesterol metabolism on mRNA and 
protein levels of apoJ, pBCEC were incubated for 24 h with vehicle (0.5% ethanol), the 
natural LXR ligands 24(S)OH-cholesterol [10 µM] or 27OH-cholesterol [10 µM], the synthetic 
LXR ligand TO901317 [2 µM], the HMG-CoA reductase inhibitor simvastatin [5 µM], or 
cholesterol [100 µM] itself. Simvastatin induced a 2.1±0.43-fold increase in apoJ mRNA 
levels while neither cholesterol, nor LXR agonists exerted significant effects on apoJ mRNA 
or protein expression levels in pBCEC (Fig. 1A). To see whether effects of simvastatin 
treatment on apoJ levels are related to the altered cellular cholesterol status elicited by the 
statin or caused by other/pleiotropic effects, pBCEC were incubated in the presence or 
absence of simvastatin [5 µM], cholesterol [100 µM], or a combination of simvastatin [5 µM] 
and cholesterol [100 µM]. Immunoblotting revealed a 2.3±0.77-fold increase in apoJ protein 
expression by pBCEC in response to simvastatin (Fig. 1B). Neither cholesterol nor a 
combination of cholesterol and simvastatin changed cellular apoJ levels. This indicates that 
effects of simvastatin on apoJ levels are likely mediated by its inhibition of cellular cholesterol 
synthesis.  
 
Since apoJ protein is known to be present in two forms (60), i.e. secreted (representing the 
more abundant form) or remaining within the cell, we examined levels of apoJ released by 
polarized pBCEC cultured on Transwell filters, to the apical (mimicking the blood-side of the 
BBB) and the basolateral (mimicking the brain parenchymal side of the BBB) compartment. 
Secretion of apoJ (during 24 h) to both the basolateral and apical compartments was 
observed, interestingly with a 3.2±0.58-fold higher amount of apoJ detected in the 
basolateral media (Fig. 1C). Furthermore, levels of apoJ in the basolateral compartment 
increased by 1.8±0.22-fold in response to simvastatin [5µM] treatment while cholesterol 




To confirm effects of 24 h simvastatin treatment on cholesterol synthesis in pBCEC, we 
performed GC-MS analysis from cell lipid extracts to measure deuterium isotopes 
incorporated into cholesterol molecules during incubation in the absence or presence of 
simvastatin in medium containing 10% deuterium water. We detected a 73.5±6.5% reduction 
in deuterium enrichment and hence a clear inhibition of cholesterol synthesis in response to 
treatment with 5 µM simvastatin (Fig. 1E). To confirm results, we additionally measured 
levels of cholesterol precursors (Fig. 1F). Here we found a reduction of desmosterol 
(72.4±3.58%), lathosterol (72.0±7.31%), lanosterol (81.2±2.37%), FF-MAS (85.1±9.81%) and 
T-MAS (69.6±4.16%) in response to simvastatin treatment. 
 
3.2. Simvastatin influences APP expression and processing pathways in 
cerebrovascular endothelial cells 
Beyond its original role in treating dyslipidemia it was shown that statin treatment reveal 
beneficial effects in progressive neurodegenerative diseases by reducing Aβ formation and 
burden (61). Therefore, we were interested to study the effects of cholesterol and simvastatin 
on mRNA and protein levels of APP, APP processing products, and APP processing 
enzymes in pBCEC (Fig. 2). We detected an increase by 78±24.7 % in relative APP mRNA 
levels in response to simvastatin treatment (5 µM, 24 h), which was accompanied by an 
equally increased (84±13.4 %) transcription of the non-amyloidogenic enzyme α-secretase 
(ADAM10) and reduced (53±28.7 %) transcription of the amyloidogenic enzyme BACE1 (β-
secretase) (Fig. 2A). By contrast, cholesterol treatment (100 µM, 24 h) neither influenced 
APP, nor ADAM10 or BACE1 mRNA expression levels in pBCEC. In line with mRNA data, 
we detected a 2.1±0.60-fold increase in cellular protein levels of full-length APP (Fig. 2C) and 
a moderate (14±3.3%) decrease in BACE activity (Fig. 2B) in response to simvastatin 
treatment. The combined treatment with cholesterol [100 µM] and simvastatin [5 µM] 
diminished effects seen with simvastatin alone from 2.1±0.60-fold to 1.5±0.34-fold increase 
in cellular APP protein levels. In additional western blot experiments we detected a 3.4-fold 
increase in CTF (C-terminal fragments), APP cleavage products representing increased APP 
processing (Fig. 2D). No significant changes in CTF levels were observed when pBCEC 
were treated with either cholesterol or a combination of cholesterol and simvastatin, 
indicating that addition of cholesterol may reverse effects observed with simvastatin. In line 
with enhanced ADAM10 expression (Fig. 2A), simvastatin treatment increased levels of the 
secreted, beneficial APP cleavage product APPα (sAPPα) by 41±0.25% (Fig. 2E). Combined 
treatment with simvastatin and cholesterol also increased sAPPα protein levels, but to lower 
extent (33±0.19%) as compared to simvastatin alone, indicating that the effect of simvastatin 
is partly mediated through inhibition of cellular cholesterol synthesis. To sum up, we 
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conclude that simvastatin treatment shifts APP processing towards the beneficial, non-
amyloidogenic pathway in cerebrovascular EC. 
 
Further analysis of the amyloidogenic products formed from APP demonstrated a shift in 
cellular and secreted Aβ oligomer levels in response to treatment with simvastatin: relative 
protein amounts of cell-associated Aβ oligomers were significantly reduced (by 50±11.8%, 
Fig. 3A), whereas extracellular Aβ oligomers detected in the medium were increased (by 
51±11.4%, Fig. 3B) as compared to control pBCEC. Aβ oligomers were detected in pBCEC 
using an amyloid oligomer specific antibody (A11), as described and characterized by 
Schweinzer et al (44). In addition, cellular uptake of [125I]-Aβ(1-40) was reduced upon 
simvastatin treatment by 17±8.5% (Fig. 3C). In subsequent transcytosis experiments we 
examined the transport of 125I labelled Aβ(1-40) from the basolateral (abluminal/brain 
parenchymal) to the apical (luminal/blood) compartment of pBCEC transwell cultures 
mimicking the BBB. Simvastatin exerted no significant effect on transport of exogenous Aβ(1-
40) across the BBB (Fig. 3D).  
 
These results taken together indicate that simvastatin treatment leads to reduced cellular 
load of cytotoxic Aβ oligomers in line with both reduced Aβ production and reduced cellular 
Aβ uptake by pBCEC, while clearance of Aβ across polarized cells is not compromised. 
 
3.3. ApoJ regulates APP protein expression, Aβ formation, and clearance in pBCEC 
To investigate potential effects of apoJ on APP expression and processing, apoJ was 
silenced using small interfering RNA. We observed a 54±2.2% and 54±1.9% reduction in 
apoJ mRNA levels using 25 nM and 50 nM of siRNA, respectively ( 
Fig. 4A), the latter yielding a more pronounced (by 56% as compared to 44%) reduction of 
cellular apoJ protein levels ( 
Fig. 4B). Thus all further studies were conducted using 50 nM of siRNA. 
 
To examine the effects of apoJ silencing on proteins involved in the amyloid pathway, 
immunoblotting of APP, cellular and secreted Aβ oligomer levels was performed. Western 
blot analysis revealed a 56±19.8% reduction of intracellular APP protein levels ( 
Fig. 4C) and a reduction by 53±28.9% of intracellular Aβ oligomer levels ( 
Fig. 4D) in response to apoJ silencing. ApoJ silencing did not affect mRNA levels of APP, 
ADAM10, BACE1, or HMG-CoA-reductase (data not shown). 
 
We next examined effects of exogenous apoJ on APP expression and processing in 
pBCEC. Porcine BCEC were incubated for 24 h in presence of 2 or 20 µg/ml of purified 
plasma apoJ (matching approximate concentrations detected in CSF and plasma, 
respectively (62). In line with the contrary results obtained during apoJ silencing experiments, 
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we detected a 3.3±1.19-fold and 2.4±0.20-fold higher amount of full-length APP protein in 
response to 2 µg/ml and 20 µg/ml apoJ treatment, respectively, while a combination of 20 
µg/ml apoJ and 5 µM simvastatin increased protein levels of full-length APP up to 2.6±0.78-
fold (Fig. 5A). On the other hand, we did not observe any significant changes in mRNA 
expression levels of genes involved in APP processing, nor HMGR, ABCA1 or SREBP2 in 
response to treatment with apoJ (Fig. 5B). Only the combined treatment with apoJ and 
simvastatin led to changes, confirming simvastatin as the major modifier. To examine the 
role of apoJ in Aβ transport across the BBB, pBCEC were grown on transwell filters, 
incubated for 2 h with 2 µg/ml exogenous apoJ added to both compartments, and 
transcytosis of radiolabelled Aβ peptides from the basolateral to the apical compartment was 
monitored. These experiments revealed that apoJ increases the transcytosis rate of [125I]-
Aβ(1-40) by 21±3.4% (Fig. 5C). In total a mean of 23.6±10.33% [
125I]-Aβ(1-40) was transported 
from the basolateral to the apical compartment, comparing to 4.6±2.80% transport of [14C]-
sucrose (Fig. 5D). Tightness of the endothelial barrier was assessed by measuring TEER 
values (Fig. 5E). TEER values rose from day 1 to day 2 after plating pBCEC on transwell 
filters from 96±9.2 to 142±18.6 ohm/cm². After induction of tight junction formation by 
addition of hydrocortisone [550 nM], TEER values increased by 2.3-fold reaching 332±24.1 
ohm/cm². Treatment of pBCEC did not affect barrier tightness. Tight junction formation in 
pBCEC incubated in presence or absence of hydrocortisone [550 nM] was also examined by 
immunofluorescence microscopy (Fig. 5F). Tight junctions were visualized by anti-ZO-1 
antibody and anti-VE-cadherin antibody. We observed a clear formation of tight junctions in 
pBCEC with and without induction with hydrocortisone. After incubation with hydrocortisone, 
pBCEC formed a more compact and organized barrier, as indicated also by TEER (Fig. 5E).  
 
These results together strongly suggest an importance of apoJ in APP production and Aβ 
transport in cerebrovascular endothelial cells. As gene transcription analysis did not reveal 
significant changes upon modulation of apoJ levels in pBCEC, we hypothesized that the 
significance of apoJ is mainly based at the posttranslational level. 
 
3.4. Aβ(1-40) affects apoJ expression and secretion in pBCEC 
Having established that cellular apoJ levels as well as exogenous apoJ do modulate 
APP/Aβ processing and metabolism, we next studied potential alterations in apoJ expression 
and secretion caused by incubation of pBCEC in the presence of increasing (25, 50 and 200 
ng/ml) concentrations of Aβ(1-40) for 1 h or 24 h. We used Aβ(1-40), since this is the most 
abundant amyloid peptide found in biological fluids and in cerebrovascular amyloid plaques 




mRNA expression analysis revealed an increase in apoJ mRNA levels by 37±9.7% and 
35±13.9%, respectively, in response to 1 h incubation with 50 and 200 ng/ml Aβ(1-40) (Fig. 
6A). Furthermore, a dose-dependent decrease in cellular apoJ protein expression was 
detected. Treatment with 25 ng/ml, 50 ng/ml, or 200 ng/ml Aβ(1-40) for 1 h led to reduction in 
cellular apoJ levels by 32±9.0%, 54±9.3% and 46±9.5%, respectively (Fig. 6C). In addition, 
the combined treatment with Aβ and apoJ decreased cellular apoJ protein levels by 
65.6±10.6%. Treatment of pBCEC with Aβ(1-40) for 24 h resulted in a less pronounced, but still 
significant reduction in cellular apoJ protein levels (by 25±17% and 29±10.6% in response to 
50 ng/ml and 200 ng/ml of Aβ(1-40), respectively; Fig. 6C, right side), and a dose-dependent 
increase in secreted apoJ protein levels (by 1.5±0.20-fold and 2.5±0.39-fold in response to 
50 ng/ml and 200 ng/ml Aβ(1-40),  respectively; Fig. 6B) These results together suggest us that 
enhanced transcription and secretion of apoJ in response to Aβ(1-40) may serve to counteract 
the Aβ challenge and protect the cells by scavenging extracellular Aβ(1-40). 
 
In cell proliferation assays using WST1 reagent (Roche), no cytotoxic effects were observed 
for any of the concentrations of Aβ(1-40) used (Fig. 6D).  
 
3.5. Effects of apoJ and Aβ(1-40) on receptors involved in Aβ clearance at the BBB  
To test whether the addition of apoJ prevents Aβ from binding to pBCEC and subsequent 
uptake, we performed an uptake assay using fluorescently (Alexa Fluor 488) labelled Aβ(1-40). 
We found that a 3 h treatment with 2 and 20 µg/ml purified apoJ led to a dose-dependent 
reduction in uptake of Alexa Fluor488 labelled Aβ(1-40) by 40±17.6% and 59±11.0%, 
respectively (Fig. 7A). An incubation time of 24 h led to an even more significant reduction in 
the uptake by 28±9.3% and 64±10.6%, respectively, confirming our hypothesis.  
 
To examine the importance and influence of receptors known to be involved in Aβ transport, 
pBCEC were incubated for 1 h with different concentrations of Aβ(1-40) or a combination of 
Aβ(1-40)  and apoJ (Fig. 7B). Interestingly, we detected a dose-dependent increase in LRP1 
mRNA levels in response to treatment with 25 ng/ml (1.5±0.28-fold), 50 ng/ml (1.9±0.25-
fold), or 200 ng/ml (2.2±0.24-fold) Aβ(1-40) as compared to pBCEC incubated in the absence 
of Aβ peptides. Stunningly, the combined treatment with Aβ(1-40) [50 ng/ml] and apoJ [2 
µg/ml], reduced LRP1 mRNA expression back to normal (untreated conditions), again in 
accordance with apoJ ‘scavenging’ extracellular Aβ.  In addition, at the highest concentration 
used (200 ng/ml), Aβ(1-40) also up-regulated mRNA levels of RAGE, LRP2 and P-glycoprotein 
(PGP)/multidrug resistance protein 1 (MDR1) by 2.1±0.55-fold, 2.3±0.48-fold and 1.6±0.22-




In order to examine the effects of Aβ(1-40) on LRP1 at the protein level, antibodies recognizing 
two different epitopes were used (Fig. 8). Antibody LRP1 (B411E2) recognizes the N-
terminus of LRP1 (63) and therefore detects the non furin-cleaved pre-mature form of LRP1 
(600 kDa) as well as LRP1 α-chain (515 kDa), whereas LRP1 (1704) binds to the C-terminus 
of LRP1 (64) and therefore recognizes the cytoplasmic domain of the membrane-bound 
receptor LRP. Aβ(1-40) treatment had no influence upon protein expression levels of the 
cytoplasmic domain of LRP1, whereas treatment with 50 ng/ml, 200 ng/ml, or a combination 
of Aβ and apoJ led to a reduction of LRP1 α-chain level by 39±3.1%, 29±11.4% and 
48±8.6%, respectively. An extended incubation period for 24 h did not confirm a dose-
dependent increase of LRP1 mRNA levels in response to Aβ(1-40) treatment (Fig. 8C). Along 
with reduced levels of LRP1 α-chain, we detected 1.6±0.20-fold and 2.4±0.92-fold higher 
levels of secreted, soluble LRP1 (sLRP1) in the supernatants in response to treatment with 
50 ng/ml and 200 ng/ml Aβ(1-40), respectively, as compared to untreated pBCEC (Fig. 8D). 
Combined treatment with 50 ng/ml Aβ(1-40) and apoJ [2 µg/ml] revealed significant increases 
(by 3.1±1.08-fold) in sLRP1 protein expression levels. 
 
In addition, mRNA levels of ADAM10 and BACE1, the two APP processing enzymes also 
known to cleave membrane bound LRP1 to yield soluble LRP1 (28,29), were significantly 
increased in response to treatment with Aβ(1-40) (Fig. 7C,D). Treatment with 50 ng/ml or 200 
ng/ml Aβ(1-40) increased relative gene expression of ADAM10 by 62±24.2% and 76±30.0%, 
respectively. Relative mRNA levels of BACE1 increased by 34±12.2% and 64±18.9% in 
response to 50 ng/ml and 200 ng/ml Aβ(1-40), respectively.  
 
In summary these results strongly suggest that exposure of porcine cerebrovascular 
endothelial cells to Aβ(1-40) induces release of LRP1 from the cell surface, potentially 
mediated by ADAM10 and/or BACE1 and that the observed differences in Aβ(1-40) transport in 
presence of apoJ are the result of an sLRP1-dependent mechanism. 
 
In subsequent studies we were interested to examine the effect of simvastatin and 
exogenous apoJ [2 and 20 µg/ml] on receptors expressed at the BBB, especially on LRP1. 
We found that simvastatin led to an increase in mRNA expression of LRP1, RAGE and PGP 
by 1.4±0.18-fold, 2.8±0.61-fold and 1.5±0.20-fold respectively (Fig. 8E). During additional 
immunoblot analysis we focused on LRP1 and confirmed an increase in protein levels by 
77±77.0% in response to simvastatin treatment (Fig. 8F). In response to 2 µg/ml and 20 
µg/ml apoJ treatment we detected an increase in LRP1 protein levels by 47±36.2% and 
54±55.0%, respectively. By immunofluorescent staining we could also observe higher 
expression of LRP1 in response to simvastatin treatment (Fig. 8G). Treatment with 20 µg/ml 
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apoJ led to an even more pronounced increase in LRP1 expression levels. Taken these data 
together, we conclude that both, simvastatin and treatment with apoJ induce levels of 
receptors expressed at the BBB, confirmed for LRP1 at the protein level.  
 
3.6. Simvastatin upregulates expression of apoJ, APP, Lrp1, ADAM10 and BACE1 in 
apoJ silenced cerebrovascular endothelial cells 
In order to examine the effects of simvastatin and Aβ treatment in apoJ silenced 
cerebrovascular endothelial cells, we performed si-RNA experiments in combination with 
simvastatin and Aβ(1-40) treatment in pBCEC. We detected significant apoJ silencing 
effects (Fig. 9A) up to 79% with all conditions tested. However, we apoJ silencing 
efficiency was reduced by simvastatin treatment (2.0±0.26-fold). Similarily, simvastatin 
increased apoJ gene expression by 2.3±0.26-fold in apoJ silenced pBCEC treated with 
50 ng/ml Aβ(1-40). Relative gene expression levels of APP (Fig. 9B), ADAM10 (Fig. 9C), 
BACE1 (Fig. 9D), and CTF protein levels (Fig. 9E) were significantly increased in 
response to simvastatin treatment in apoJ silcenced cells, regardless whether cells were 
coincubated with Aβ(1-40). Treatment with Aβ(1-40), on the other hand, did not reveal 
significant changes on APP, LRP1, ADAM10 or BACE1 mRNA expression nor CTF 
levels in apoJ silenced pBCEC. Although these results alltogether have to be interpreted 
with caution since simvastatin treatment appeared to inhibit silencing efficiency for apoJ, 
they suggest that simvastatin effects are maintained (with the exception of BACE1) 
under apoJ-silenced conditions in pBCEC.  
 
3.7. Simvastatin affects APP processing and apoJ protein expression in 3xTg AD mice 
In order to investigate in vivo effects of simvastatin on APP processing and apoJ 
expression at the BBB in a whole animal model, 3xTg AD and Non-Tg mice were gavaged 
with or without 40 mg/kg simvastatin in 0.2% agarose in PBS for 21 days. 3xTg AD mice are 
characterized by an overexpression of APP, presinilin1 and MAPT (microtubule associated 
protein tau) (65) and are prone to cerebrovascular/BBB dysfunction (66,67). In whole brain 
RNA of these animals we found a 2.5±1.10-fold increase in APP mRNA levels compared to 
Non-Tg mice (Fig. 10A). Moreover, we detected a clear 4.1±0.77-fold increase in Aβ 
oligomer levels in mBCEC isolated from 3xTg AD mice as compared to Non-Tg controls (Fig. 
10B). Protein levels of the C-terminal fragments (CTF) - cleavage products of APP - revealed 
a 1.7-fold increase in 3xTg AD compared to Non-Tg mice, whereas simvastatin led to 
reduction in CTF levels by 50% in these mice indicating decreased APP processing in 
response to simvastatin (Fig. 10C). Simvastatin increased protein levels of apoJ in mBCEC 
of Non-Tg mice by 42% (Fig. 10D). Also, we found 2.5-fold higher apoJ protein levels in 3xTg 
AD mice compared to Non-Tg control mice. To further examine the role of receptors 
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expressed in endothelial cells in in vivo studies, RT-qPCR of mBCEC from 3xTg AD mice 
and Non-Tg control was performed. We found a 3.5±0.54-fold higher gene expression level 
of LRP1 in simvastatin treated 3xTg AD mice compared to Non-Tg controls (Fig. 10E). 
Further, treatment with 40 mg/kg simvastatin by oral gavage for 3 weeks increased LRP1 
gene expression in 3xTg animals by 2.4±0.54-fold. In addition, mRNA levels of LRP2 of 
mBCEC from simvastatin treated 3xTg AD mice were increased up to 3.5±0.55-fold as 
compared to Non-tg animals and 2.4±0.54-fold relative to vehicle control treated 3xTg AD 
mice, whereas the expression profile of RAGE revealed unchanged.  
 
4. DISCUSSION 
In this study we demonstrate pronounced effects of the HMGCo-A reductase inhibitor 
simvastatin in primary brain capillary endothelial cells (BCEC) indicating a close interplay of 
cellular cholesterol metabolism, apoJ expression/secretion and Aβ production, metabolism, 
and clearance at the blood-brain interface. 
Primary porcine brain capillary endothelial cells (pBCEC) were used as an in vitro model for 
our studies. These cells were shown to be actively involved in HDL biogenesis and Aβ 
processing at the blood-brain interface (44,68). Several studies have stated a correlation 
between cholesterol homeostasis in the brain, which seems to be isolated from that in the 
periphery, and Aβ metabolism (43,44,68). It is suggested that increasing cholesterol levels 
increase Aβ abundance. HDL, on the other hand was shown to have a protective role in 
neuroinflammation, oxidative stress and also in Aβ metabolism (69,70). It was demonstrated 
that HDL-like particles in the brain can bind to Aβ peptides and facilitate its clearance across 
the BBB (69,71). Furthermore, AD patients reveal significantly higher LDL cholesterol and 
significantly reduced HDL cholesterol (72). They were also reported to have higher apoJ 
expression levels, in particular present in neuritic plaques and cerebrovascular deposits (36). 
ApoJ reveals, in addition to its rather minor function in lipid trafficking, chaperone function, 
where it is involved in Aβ binding and transport (43). It was reported that apoJ is able to bind 
soluble Aβ with high affinity, especially monomeric Aβ(1-40), rather than Aβ aggregates (73). 
Furthermore, apoJ is fully functional to interact with Aβ when it is associated with HDL (74). 
Therefore, higher apoJ levels might be a marker of prevalent dementia but are not linked with 
risk of future dementia (75). Since more than 80% of AD patients also establish amyloid 
deposition in cerebral vessels (6), and cerebrovascular dysfunction was reported in 3xTg AD 
mice (66,67), we used this AD model in addition to non-transgenic animals for in vivo studies. 
 
To examine the correlation of HDL biogenesis and apoJ, in initial in vitro experiments we 
determined whether regulators of the cellular cholesterol metabolism, such as the natural 
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LXR agonist 24(S)-hydroxycholesterol, 27-hydroxycholeseterol, the synthetic LXR agonist 
TO901317, cholesterol, or simvastatin - an inhibitor of HMGCo-A reductase and thus of 
cholesterol biosynthesis - influences apoJ expression in pBCEC. Only simvastatin markedly 
increased apoJ mRNA and cellular protein levels, whereas a combination of simvastatin and 
cholesterol did not change apoJ protein levels (Fig. 1A, B). This indicates that the cholesterol 
reducing effects of statin treatment causes observed change in apoJ levels, rather than 
cholesterol-independent “pleiotropic” effects. Preliminary results suggest that – in contrast to 
apoJ - simvastatin does not alter apoA-I expression in pBCEC, whereas apoE is not 
expressed at all in pBCEC (unpublished observations). In transwell studies we observed 
significantly higher secretion of apoJ towards the basolateral compartment when pBCEC 
were treated with simvastatin (Fig. 1D). During in vivo studies we detected higher apoJ 
protein levels in cerebrovascular endothelial cells isolated from 3xTg AD mice as compared 
to Non-Tg mice (Fig. 10D). Interestingly, patients suffering CAA also reveal a higher apoJ 
plasma profile (42). In addition and in accordance with our in vitro results, administration of 
simvastatin for 21 d increased apoJ levels in mBCEC isolated from Non-Tg mice. Our data 
indicate that simvastatin, a well-known inhibitor of cellular cholesterol synthesis, has the 
potential to enhance apoJ synthesis and secretion pathways in cerebrovascular endothelial 
cells. 
 
In transwell experiments we determined polarized secretion of apoJ to the basolateral and 
apical compartment of the pBCEC monolayer. We detected predominant secretion of apoJ to 
the basolateral side (Fig. 1C). Also apoA-I is primarily secreted towards the brain 
compartment of the pBCEC monolayer and ABCA1 is localized at the basolateral membrane 
of pBCEC (68). Recently we reported that PLTP, another key protein involved in HDL 
biogenesis and remodelling, is mainly secreted towards the brain parenchymal side of the 
BBB (48), and our previous findings revealed that sAPPα (the beneficial cleavage product of 
APP) is also highly secreted to the basolateral side (44) of the BBB model. Thus, the brain 
parenchymal side of the BBB represents an important area for amyloid and cholesterol 
metabolism. 
 
When examining effects of reduced cellular cholesterol synthesis in BCEC on APP 
processing, we observed increased APP mRNA and protein, increased secretion levels of 
the beneficial cleavage product sAPPα and ADAM10 mRNA expression in response to 5 µM 
simvastatin treatment, whereas relative gene expression as well as activity of the Aβ peptide 
forming β-secretase (BACE1) was decreased (Fig. 2B). A simultaneous treatment with 
cholesterol and simvastatin reduced APP and CTF levels, and therefore APP expression and 
processing as compared to solely simvastatin treatment (Fig. 2C,D). Hence, we conclude 
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that also here effects seen with simvastatin are caused by depletion of cellular cholesterol by 
simvastatin. Barrett et al. identified a cholesterol-binding domain within the APP 
transmembrane domain (76). Due to the fact that the cholesterol-binding site is immediately 
adjacent to the α-secretase cleaving site, it is hypothesized that binding of cholesterol may 
drive APP processing towards the amyloidogenic pathway. A reduction and redistribution of 
cellular cholesterol pools could account for this effect observed in statin treated pBCEC. 
Also, dysregulation of cholesterol trafficking was reported to interfere with APP metabolism 
since α-/β-secretase processing occurs within cholesterol rich lipid rafts in the membrane 
(77,78). Therefore, cholesterol depletion decreases membrane fluidity and thus leads to 
enhanced α-secretase activity (79). Taking these findings together with the fact that lower 
cellular cholesterol synthesis due to simvastatin treatment enhances gene expression of APP 
and α-secretase ADAM10 as well as sAPPα production, we conclude that simvastatin helps 
to direct APP towards the neuroprotective, non-amyloidogenic APP processing pathway in 
cerebrovascular EC. We earlier reported on modulation of cellular cholesterol synthesis by 
simvastatin and effects on APP production and processing at the blood-brain interface in 
vitro (44). Also in neurons activities of α- and β secretases display a dependency on 
membrane cholesterol contents (80). Simons et al., for instance, reported that in cultured 
hippocampal neurons cholesterol depletion in response to combined treatment with 
lovastatin and methyl β-cyclodextrin inhibited Aβ production (81). Moreover, Cordy et al. 
demonstrated that Aβ generation in a neuronal cell line depends on lipid rafts. Changes in 
cholesterol and lipid distribution within cell membranes, which take place during aging, lead 
to higher concentrations of BACE and other amyloidogenic enzymes in lipid rafts and 
therefore more Aβ is produced (82). In addition, several studies reported that statin treatment 
decreased Aβ loads in animal models (21,83). When we performed in vivo studies, we found 
decreased production of both CTFα and β in cerebrovascular cells isolated from 3xTg AD 
mice in response to treatment with simvastatin (Fig. 10C). This indicates reduced APP 
processing and thus potentially reduced Aβ production in mBCEC. 
 
Upon simvastatin treatment cell-associated oligomers are reduced in pBCEC, which may 
be beneficial for the cell - concomitantly, however oligomers/Aβ in the supernatants are 
increased. Depending on the fate of these oligomers, it is important to note that they may 
add an amyloidogenic component to simvastatin’s effects to surrounding cells. We also 
studied uptake and transport of Aβ(1-40) in cerebrovascular endothelial cells. Uptake of [
125I]-
labelled Aβ(1-40) in pBCEC was reduced in response to simvastatin treatment (Fig. 3). We 
conclude that reduced cellular cholesterol synthesis leads to a reduced Aβ uptake. Many 
receptors at the BBB are involved in the uptake of amyloid fragments, with LRP1 reported as 
the most important receptor to clear amyloid peptides from the brain and efflux them to the 
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plasma (84). By immunoblot analysis and immunofluorescence microscopy we demonstrate 
that simvastatin treatment increases LRP1 protein levels in pBCEC (Fig. 8F, G).  In addition, 
we observed that Aβ(1-40) increased mRNA expression of RAGE, PGP, LRP2, but most 
pronouncedly of LRP1 in pBCEC (Fig. 7B). Also, gene expression of LRP1 and LRP2, but 
not of RAGE, was shown to be higher in mBCEC of simvastatin treated 3xTg AD mice 
compared to Non-Tg control animals (Fig. 10E). In western blot analysis we observed a 
reduction of LRP1 α-chain, whereas the cytoplasmic domain remained unchanged in 
response to Aβ(1-40) treatment (Fig. 8). Western blots performed with secreted proteins 
showed an increase in soluble LRP1 in response to 1 h treatment with Aβ(1-40). In further 
experiments we found that gene expression of both, BACE1 and ADAM10 was increased in 
response to Aβ(1-40) treatment (Fig. 7C,D). It was reported that α-secretase ADAM10, which 
belongs to the group of metalloproteinases, and β-secretase BACE1 are responsible for 
LRP1 shedding, which results in the production of sLRP1 (28,29). Surprisingly, we found that 
the combined treatment of Aβ(1-40) and apoJ did not enhance expression of LRP and other 
receptors at the BBB, whereas treatment with just 20 µg/ml apoJ increased the LRP1 β-chain 
in both, western blot analysis and with immunofluorescence microscopy (Fig. 8F,G). As we 
found reduced uptake of Aβ(1-40) in the presence of apoJ (Fig. 7A), we hypothesize that apoJ 
binds and scavenges Aβ in the extracellular space and thereby uptake and toxicity is 
reduced in pBCEC. In addition, we observed primarily enhanced secretion of LRP1 to the 
medium in response to additional treatment with Aβ(1-40), Therefore, we postulate that in 
pBCEC clearance/uptake of Aβ is activated through other mechanisms/receptors rather than 
membrane bound LRP1. Future studies will address this question. 
 
In a series of experiments, we examined the effects of exogenous, purified plasma apoJ 
treatment as well as of apoJ silencing on mRNA and protein expression levels of genes 
involved in amyloid and cholesterol metabolism. During silencing studies, we observed that a 
reduction of apoJ using small interfering RNA lead to decreased full-length APP protein ( 
Fig. 4C). Treatment with exogenous apoJ [2 µg/ml and 20 µg/ml], on the other hand, 
significantly increased APP protein levels (Fig. 5A). Therefore, we postulate a close 
connection and an important role of apoJ in APP metabolism in the cerebrovasculature.  
 
When further elucidating the effects of amyloid peptides and apoJ expression and 
secretion, we found that Aβ(1-40) increased apoJ mRNA and secreted protein levels, whereas 
cellular apoJ levels were reduced after 1 h treatment and to a lesser extent after 24 h 
treatment (Fig. 6). As it was shown that apoJ tends to colocalize with amyloid plaques (85) 
and may avidly bind to Aβ (86), the observed data suggest that upon treatment with Aβ more 
apoJ is translated and secreted to the extracellular space to bind to Aβ(1-40) peptides. In 
contrast, it was reported by Wang et al. that treatment with Aβ42 led to overexpression of 
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intracellular apoJ, but levels of secreted apoJ remained unchanged in primary hippocampal 
neurons (87). This indicates, that apoJ is regulated differently in different brain cell types in 
response to Aβ treatment.  Zlokovic et al. and Merino-Zamorano et al. reported, however, 
that apoJ can facilitate Aβ clearance across well-established in vitro BBB models (43,88). In 
transport studies we observed increased clearance of [125I]-labelled Aβ(1-40) from the 
basolateral to the apical side in the presence of apoJ, whereas overall cellular uptake was 
reduced (Fig. 5C, Fig. 7A). This is in accordance with the studies performed by Cole et al., 
who reported that apoJ blocks binding, uptake and degradation of Aβ42 in rat microglia (89). 
In other studies it was shown that apoJ reduced uptake of Aβ oligomers and fibrils in primary 
human adult microglia (90). In primary human astrocytes, on the other hand, just uptake of 
Aβ oligomers was impaired, whereas Aβ fibrils uptake remained unchanged (90).  
 
As the function of apoJ in amyloid metabolism is quite controversial we were aiming to 
elucidate the mechanism of this chaperone in correlation with cholesterol metabolism in APP 
processing at the BBB. We clearly demonstrate that simvastatin treatment, which blocks 
cellular cholesterol synthesis, increases expression of APP and the α-secretase ADAM10, 
reduces the β-secretase BACE1 and hence, shifting APP processing towards the non-
amyloidogenic pathway in cerebrovascular endothelial cells (Fig. 11). Moreover, due to 
simvastatin induced cholesterol depletion cellular Aβ uptake is decreased, leaving secreted 
Aβ increased. Our findings suggest a predominant secretion of apoJ from cerebrovascular 
endothelial cells to the brain parenchymal (basolateral) site of the BBB, where it can bind to 
Aβ and also helps in amyloid clearance across the BBB. Experiments showing increased 
secretion of apoJ to the extracellular space in response to treatment with soluble Aβ(1-40) also 
confirm this conclusion. Moreover, we clearly demonstrated that simvastatin and therefore 
reduced cellular cholesterol synthesis can regulate apoJ expression in brain endothelial cells 
both in vitro and in vivo. Results obtained from in vitro studies indicate a strong correlation of 
apoJ and APP protein levels. Addition of exogenous apoJ increased APP, whereas apoJ 
silencing reduced full-length APP and also cellular Aβ levels. Furthermore, we found that the 
presence of Aβ favorably leads to the secretion of the usually membrane bound receptor 
LRP1 in porcine cerebrovascular endothelial cells.  
 
5. CONCLUSION 
To sum up we suggest a close connection of statin treatment, apoJ and amyloid processing 
at the blood-brain interface. Future in vivo studies are aiming to elucidate and understand 
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AD: Alzheimer’s Disease 
Aβ: amyloid-beta peptide 
ApoJ: apolipoprotein J 
APP: amyloid precursor protein 
BBB: blood-brain barrier 
CAA: cerebral amyloid angiopathy 
CSF: cerebrospinal fluid 
CTF: C-terminal fragment 
HPRT1: hypoxanthine phosphoribosyltransferase 1 
ISF: interstitial fluid 
LRP1: low-density lipoprotein receptor-related protein 1 
mBCEC: primary murine brain capillary endothelial cells 
pBCEC: primary porcine brain capillary endothelial cells 
PGP: P-glycoprotein 
RAGE: receptor for advanced glycation end products 




Gene Sequence (5’-3’) Amplicon 
length (bp) 
ssADAM10 F,            AGCAACATCTGGGGACAAAC 219 
R,             CTTCCCTCTGGTTGATTTGC 
ssAPP F,            CGTGGGAGTTTAGCTGCTTC 122 
R,             TCAAATGCAATCGTGGAAAA 
ssAPOJ F,             CCTTCTTCGACATGATCCAC 282 
R,             AGAGCTTGCTGAACTTCTCC 
ssBACE1 F,               TGGACTGCCTCATGGTGTG 155 
R,           GTGACCAAAGTGAACCACCG 
ssHPRT1 F,            AGGACCTCTCGAAGTGTTGG 247 
R,           CAGATGGCCACAGGACTAGA 
ssLRP1 F,   GCAGATGTATCAACATCAACTGG 98 
R,        GGGTGCTAGAGCAAGAGTGG 
ssLRP2 F,           CATGTTTGTGTCCAGCCATC 191 
R,           TCGTCACTTCCATCTCCACA 
33 
 
ssPGP (MDR-1) F,   GAATTGCCCAGATAACAGCACCA 123 
R,        GCCAGGCACCAGAACGAAAC 
ssRAGE F,          TCAAAACATCACAGCCCGGA 129 
R,         GGAGTCAGGACCTTCCAAGC 
mmLRP1 F,           CCGCATCTTCTTCAGTGACA 96 
R,          ACAGAGCCCACATTTTCCAC 
mmRAGE F,        GGGAGGCCTGGGAGTAGTAG 92 
R,             ATTCAGCTCTGCACGTTCCT 
mmAPP F,          TCCGAGAGGTGTGCTCTGAA 115 
R,     CCACATCCGCCGTAAAAGAATG 
ssHMGR F,             CTTGTTCACGCGCACAGTCG 207 
R,          GACAGCCAGAAGGAGAGCCA 
ssABCA1 F,                  GCCATTCTCCGGGCCAAC  252 
R,                     GGCTTCACGCCGCTGAT              
ssSREBP2 F,               GCTTCTCCCCCTACTCCATC 151 
R,          GAGAGGCACAGGAAGGTGAG 
mmHPRT1, 
mmLRP2 
QuantiTect Primer Assay (Qiagen)  
Table 1: Primer sequences for porcine (ss) and murine (mm) genes used for real time PCR 
 
siRNA Sequence (5’- 3’) Company 
ApoJ_1 5’- ACA GAU AAA GAC CCU AAU ATT -3’ Microsynth 
ApoJ_2 5’- AUU UCC CGU GUG CCA CUA ATT -3’ Microsynth 
ApoJ_3 5’- UUC CCU AUC ACU UCC CUG ATT -3’ Microsynth 







Fig. 1: Simvastatin increases mRNA and protein expression of apoJ in pBCEC. (A) 
Brain capillary endothelial cells were treated for 24 h in the absence (vehicle control) or 
presence of 10 µM 24OH-cholesterol (24OH-C), 10 µM 27OH-cholesterol (27OH-C), 2 µM 
TO, 100 µM cholesterol or 5 µM simvastatin. 0.5% ethanol in serum-free medium was used 
as vehicle control. Total RNA was isolated, reverse-transcribed and subjected to qPCR using 
SYBR green technology and HPRT1 as a reference gene. (B) pBCEC were incubated 24h in 
the absence (vehicle control) or presence of simvastatin [5µM], cholesterol [100 µM] and a 
combination of cholesterol and simvastatin. Western blot analysis of intracellular apoJ was 
performed using Rabbit-anti-clusterin antibody for detecting apoJ. (C) pBCEC were 
incubated on multiwell transwell filters to detect either apical (“blood compartment”) or 
basolateral (“brain compartment”) secretion of apoJ. (D) pBCEC were treated for 24 h with 
simvastatin [5µM] or cholesterol [100 µM] in serum-free medium and western blot analysis 
was performed from proteins precipitated from basolateral media. (C,D) Apical (1.5 ml) and 
basolateral (2.6 ml) media were collected, TCA-precipitated, and aliquots corresponding to 1 
ml of supernatant and normalized to total cell cellular protein contents were subjected to 
immunoblot analysis using SDS-PAGE (4-12%) and PVDF membranes. The antibody 
Rabbit-anti-clusterin was used to detect secreted apoJ protein levels (E) To measure 
cholesterol synthesis, enrichment of deuterated water in the total cellular cholesterol fraction 
was determined using GC-MS analysis. All data represent mean±SD from 4 independent 
experiments performed in triplicates. (F) pBCEC were treated for 24 h with simvastatin [5 
µM], or vehicle control (0.5% ethanol) and cellular lipids were isolated with Folch’s solvent. 
Cholesterol precursors were measured using GC-MS analysis as described under Materials 
and Methods. Data represent mean±SD from 4 independent experiments performed in 






Fig. 2: Simvastatin affects APP expression and processing along with APP processing 
enzymes in pBCEC. Brain capillary endothelial cells were treated for 24 h in presence of 
vehicle control [0.5% ethanol], cholesterol [100 µM], or simvastatin [5 µM], or a combination 
of cholesterol and simvastatin. (A) Total RNA was isolated, reverse-transcribed, and qPCR 
analysis was performed with CFX 96 real time system (Bio-Rad) using SYBR Green 
technology. mRNA expression levels were calculated using ∆∆Ct method and HPRT1 as 
reference gene. Data represent mean±SD from 4 independent experiments. (B) Cell lysates 
of 100 µg protein were subjected to BACE1 activity assay kit provided by Abcam. Data 
represent mean±SD from 4 independent experiments performed in triplicates. (C,D) 
Immunoblot analysis was performed with extracted cell lysates and rabbit anti Amyloid 
Precursor Protein, C-Terminal antibody was used to detect APP and CTF (C-terminal 
fragments). Band intensities were evaluated densitometrically using β-actin for normalization. 
Blot is representative for one and data shown are mean±SD from 4 independent experiments 
performed in triplicates. # indicates significance (p<0.05) of simvastatin [5µM] as compared 
to combined treatment with simvastatin [5 µM] and cholesterol [100 µM]. (E) Media were 
collected, TCA-precipitated and subjected to western blot analysis was performed. Samples 
were normalized to total cellular protein and Anti-beta-Amyloid 1-16 (6E10) antibody was 
used for detecting sAPPα. Data represent mean±SD from 3 independent experiments 





Fig. 3: Simvastatin treatment decreases cellular Aβ oligomers and Aβ uptake leaving 
extracellular Aβ oligomer levels increased. Brain capillary endothelial cells were 
incubated for 24 h in the presence or absence of simvastatin [5µM]. Ethanol [0.5%] was used 
as vehicle control. (A) Proteins from cell lysates were separated by SDS-PAGE and 
immunoblotting was performed using A11 rabbit-anti-amyloid oligomer antibody to detect 
cell-associated Aβ oligomers. Band intensities were evaluated densitometrically using β-Actin 
for normalization. (B) Extracellular proteins were TCA-precipitated from supernatants and 
aliquots were normalized to total cellular protein prior to immunoblot analysis. Secreted Aβ 
oligomers were detected using A11 rabbit-anti-amyloid oligomer antibody. (A,B) Blots shown 
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are representative for one and data represent mean±SD from 4 independent experiments. 
(C) pBCEC were cultured in the presence or absence of vehicle control or  simvastatin [5µM]. 
Uptake assay was performed by incubating cells with [125I]-Aβ(1-40) [0.3 nM] for 22 h. Data 
shown represent cpm/mg protein and mean±SD from 3 independent experiments performed 
in triplicates. (D) To examine the influence of an impaired cellular cholesterol metabolism on 
Aβ(1-40) transport across the BBB, pBCEC were split onto transwells, treated with simvastatin 
[5 µM] and  [125I]-Aβ(1-40) was added to the basolateral compartment. Transcytosis from the 
brain to the blood compartment was examined using radioactively labelled nucleotides. Data 









Fig. 4: Effects of apoJ silencing on APP and Aβ oligomers. (A) ApoJ was silenced by 
incubating pBCEC for 30 h with 25 nM or 50 nM siRNA. Scrambled siRNA was used as non-
targeting control (NTC). (B,C) Immunoblot analysis was performed from extracted cell 
lysates. β-actin was used for normalization and densitometric evaluation. (B) ApoJ was 
detected using rabbit-anti-clusterin antibody. (C) Full-length APP was detected by using 
antibody rabbit-anti-β-APP. (C,D) Western blotting of APP and cellular Aβ oligomers was 
performed using extracts from cell lysates and rabbit-anti-β-APP and A11 rabbit-anti-amyloid 
oligomer antibodies. Data represent mean±SD from 4 independent experiments. *p<0.05; 





Fig. 5: Effects of addition of purified apoJ on APP and Aβ oligomer levels and 
transport. Cerebrovascular endothelial cells were treated for 24 h with 2 µg/ml or 20 µg/ml 
apoJ or a combination of apoJ [2 µg/ml] and simvastatin [5 µM]. (A) Immunoblot analysis was 
performed using rabbit-anti-β-APP antibody and β-actin for normalization. Data represent 
mean±SD from 4 independent experiments performed in triplicates. (B) Cells were harvested 
and RNA isolation and RT-qPCR was performed as described in Experimental procedures 
using ∆∆Ct method. Data represent mean±SD from 3 independent experiments. (C) pBCEC 
were grown on transwell filters and treated with apoJ [2 µg/ml]. Transport was examined by 
adding [125I]-Aβ(1-40) to the basolateral compartment and [
14C]-sucrose as a non-diffusion 
control. After 2 h incubation time, increase of Aβ(1-40) in the apical compartment was 
measured by using a γ-counter. Data represent mean±SD from 3 independent experiments 
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performed in triplicates. (D) Transport of [14C]-sucrose and [125I]-Aβ(1-40) from the basolateral 
to apical compartment of the endothelial barrier was measured after 2 h using a ß- and a γ-
counter, respectively and data is shown in %. (E) Transendothelial electrical resistance 
(TEER) of pBCEC monolayers was measured using an EndOhm tissue resistance chamber 
and Evohm ohmmeter. On day 2 tight junction formation was induced incubating pBCEC with 
hydrocortisone [550 nM] for 24h. (F) Brain capillary endothelial cells were seeded on 
collagen G coated FlexiPerm slides, incubated in the absence or presence of hydrocortisone 
(HC, 550 nM, 24h) and immunofluorescently stained as described in Experimental 
procedures using anti-ZO1 (red) or anti-VE-cadherin (green) antibody. Cell nuclei were 






Fig. 6: Aβ(1-40) increases apoJ mRNA expression and mobilizes apoJ secretion by 
pBCEC. pBCEC were treated with increasing concentrations of Aβ(1-40) [25 ng/ml, 50 ng/ml, 
200 ng/ml] or a combination of apoJ  [2µg/ml] and Aβ(1-40) [50 ng/ml] for 1 h (A,C) and for 24 h 
(B, C), respectively. (A) Total RNA was isolated, reverse-transcribed and gene expression 
analysis was performed using ∆∆Ct method and normalization to HPRT1. (B, C) 15 µg of 
intracellular or secreted proteins –normalized to total cellular protein- were isolated from cell 
lysates and supernatants via TCA precipitation, respectively. Immunoblotting was performed 
using SDS-PAGE (4-12%) and PVDF membranes. β-Actin was used as loading control. Data 
represent mean±SD from 4 (A, B) and 5 (C) independent experiments. (D) Aβ(1-40) treatment 
does not influence cell viability. Cell viability test was performed using Cell Proliferation 










Fig. 7: ApoJ inhibits uptake of Aβ(1-40) by pBCEC and scavenges the effects of Aβ(1-40) 
on transcription of receptors known to be involved in amyloid transport. (A) Uptake 
assay was performed using Alexa Fluor 488 (AF488) labelled Aβ(1-40). pBCEC were incubated 
with AF488- Aβ(1-40) in the presence or absence of 2µg/ml and 20 µg/ml purified apoJ for 3h 
and 24h. Cells were lysed with 0.3 N NaOH and uptake was measured fluorescently using a 
fluorescent plate reader. Data represent mean±SD from 3 independent experiments 
performed in quadruplicates. (B) pBCEC were incubated for 1 h with increasing 
concentrations of Aβ(1-40) [25 ng/ml, 50 ng/ml, 200 ng/ml], or a combination of Aβ(1-40) [50 
ng/ml] and apoJ [2 µg/ml]. RNA was isolated, and RT-qPCR was performed for low-density 
lipoprotein receptor-related protein 1 and 2 (LRP1, LRP2), receptor for advanced glycation 
end products (RAGE), and P-glycoprotein (PGP) using ∆∆Ct method and HPRT1 as 
housekeeping gene. Data represent mean±SD from 4 independent experiments performed in 
triplicates. # indicates significance (p<0.05) of combined treatment with Aβ(1-40) [50 ng/ml] and 
apoJ [2 µg/ml] as compared to 50 ng/ml Aβ(1-40). (C, D) Total RNA was isolated, reverse-
transcribed and qPCR analysis was performed for α-secretase (ADAM10) and β-secretase 
(BACE1) with CFX 96 real time system (Bio-Rad) using SYBR Green technology. mRNA 
expression levels were calculated using ∆∆Ct method and HPRT1 as house-keeping gene. 
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Data represent mean±SD from 3 (C) and 5 (D) independent experiments performed in 







Fig. 8: Aβ(1-40) treatment increases sLRP1 protein levels in pBCEC. (A-C) To analyse 
protein levels of LRP1 α- and β-chain (B411E2) and the transmembrane domain (1704), 
pBCEC were treated for 1 h (A,B) and 24h (C) with increasing concentrations of Aβ(1-40) [25 
ng/ml, 50 ng/ml, 200 ng/ml] or a combination of Aβ(1-40) [50 ng/ml]/apoJ [2 µg/ml]. Western 
blot analysis was performed after extracting proteins from cell lysates. β-Actin was used as 
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loading control and for normalization. Data represent mean±SD from 3 independent 
experiments. (D) Secreted, soluble LRP1 (sLRP1) protein levels were detected in the 
medium after 24 h incubation with increasing concentrations of Aβ(1-40). Antibody LRP1 
(B411E2) was used to detect sLRP1. Aliquots loaded were normalized to total cellular 
protein. Data represent mean±SD from 5 independent experiments. (E) pBCEC were treated 
in the absence (0.5% Ethanol as vehicle control) and presence of simvastatin [5 µM] for 24h. 
RNA was isolated, reverse transcribed and subjected to RT-qPCR analysis. Data represent 
mean±SD from 5 independent experiments performed in triplicates. (F) Brain capillary 
endothelial cells were treated for 24h in the absence (0.5% Ethanol as vehicle control) and 
presence of simvastatin [5 µM] and apoJ [2 and 20 µg/ml]. Western blot was performed from 
intracellular protein using anti-Lrp1 (1704) antibody. Data represent mean±SD from 4 
independent experiments performed in triplicates. (G) pBCEC were splitted on collagen G 
coated FlexiPerm Slides, treated with 5 µM simvastatin and 20 µg/ml apoJ and subjected to 
immunofluorescence microscopy using anti-rabbit-Lrp1 (1704) (red) as described in the 






Fig. 9: Effects of simvastatin and Aβ treatment in apoJ silenced pBCEC. ApoJ was 
silenced by incubating pBCEC for 30 h with 50 nM siRNA. Scrambled siRNA was used as 
non-targeting control (NTC). In parallel, pBCEC were treated with simvastatin [5 µM] and/or 
Aβ(1-40) [50 ng/ml] as described in Methods. (A-E) Total RNA was isolated, reverse-
transcribed, and qPCR analysis was performed with CFX 96 real time system (Bio-Rad) 
using SYBR Green technology. mRNA expression levels were calculated using ∆∆Ct method 
and HPRT1 as reference gene. Data represent mean±SD from 3 independent experiments 
performed in triplicates. (F) Immunoblot analysis was performed with extracted cell lysates 
and rabbit anti Amyloid Precursor Protein, C-Terminal antibody was used to detect APP and 
CTF (C-terminal fragments). Band intensities were evaluated densitometrically using β-actin 
for normalization. Blot is representative for one and data shown are mean±SD from 3 





Fig. 10: Simvastatin (40 mg/kg) treatment in vivo affects APP processing, apoJ and 
LRP1 expression in BCEC. Female 3xTg AD mice and Non-Tg mice (aged 12 months and 
older) were daily gavaged for 21 days with 40 mg/kg simvastatin in 0.2% Agarose in PBS. 
(A) Relative mRNA levels of APP in whole brain were analysed by RT-qPCR using HPRT1 
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as housekeeping gene. (B) Western blot analysis of Aβ oligomer levels in mBCEC of 3xTg 
AD mice as compared to Non-Tg mice. β-Actin was used as loading control  (C, D) Western 
blot analysis of C-terminal fragment (CTF) and cellular apoJ levels in 3xTg AD mice as 
compared to Non-Tg mice and to simvastatin treatment was performed with mBCEC using β-
Actin as loading control and for normalization. (E) RNA was isolated from mBCEC, reverse-
transcribed to cDNA. RT-qPCR analysis was performed for low-density lipoprotein receptor-
related protein 1 and 2 (LRP1, LRP2) and receptor for advanced glycation end products 
(RAGE) using ∆∆Ct method and HPRT1 as reference gene. All data represent mean±SD in 
















Fig. 11: Scheme depicting regulatory effects of simvastatin and apoJ at the BBB. 
Simvastatin, an inhibitor of cellular cholesterol synthesis, increases expression of the α-
secretase ADAM10 and reduces expression and activty of the β-secretase BACE1, thereby 
shifting APP processing towards the non-amyloidogenic pathway. Further, simvastatin 
induces expression and secretion of apoJ predominantly to the basolateral compartment. 
Both, simvastatin and apoJ increase expression of APP and reduce Aβ uptake. In addition, 
apoJ facilitates transcytosis of Aβ from the basolateral to the apical compartment. Increased 
levels of Aβ in the cell surrounding as well as simvastatin induce expression of LRP1 and 
increase secretion of apoJ, faciliating thus processes leading to clearance of Aβ across the 
endothelial barrier.  
  
 
 
 
 
 
 
